These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 27761233)

  • 1. Using best practice to create a pathway to improve management of irritable bowel syndrome: aiming for timely diagnosis, effective treatment and equitable care.
    Williams M; Barclay Y; Benneyworth R; Gore S; Hamilton Z; Matull R; Phillips I; Seamark L; Staveley K; Thole S; Greig E
    Frontline Gastroenterol; 2016 Oct; 7(4):323-330. PubMed ID: 27761233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapist telephone-delivered CBT and web-based CBT compared with treatment as usual in refractory irritable bowel syndrome: the ACTIB three-arm RCT.
    Everitt H; Landau S; Little P; Bishop FL; O'Reilly G; Sibelli A; Holland R; Hughes S; Windgassen S; McCrone P; Goldsmith K; Coleman N; Logan R; Chalder T; Moss-Morris R
    Health Technol Assess; 2019 Apr; 23(17):1-154. PubMed ID: 31042143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Negative Effects on Psychological Health and Quality of Life of Genuine Irritable Bowel Syndrome-type Symptoms in Patients With Inflammatory Bowel Disease.
    Gracie DJ; Williams CJ; Sood R; Mumtaz S; Bholah MH; Hamlin PJ; Ford AC
    Clin Gastroenterol Hepatol; 2017 Mar; 15(3):376-384.e5. PubMed ID: 27189912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of medical costs generated by IBS patients in primary and secondary care in the Netherlands.
    Flik CE; Laan W; Smout AJ; Weusten BL; de Wit NJ
    BMC Gastroenterol; 2015 Nov; 15():168. PubMed ID: 26612205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feasibility, acceptability and cost efficiency of using webinars to deliver first-line patient education for people with Irritable Bowel Syndrome as part of a dietetic-led gastroenterology service in primary care.
    Williams M; Barclay Y; Harper L; Marchant C; Seamark L; Hickson M
    J Hum Nutr Diet; 2020 Dec; 33(6):758-766. PubMed ID: 32816367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Faecal calprotectin levels after rifaximin treatment in patients with irritable bowel syndrome with diarrhoea: A single-center prospective study.
    Safwat E; Salah M; Hussein H
    Arab J Gastroenterol; 2020 Dec; 21(4):273-277. PubMed ID: 32928705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcomes at 12 months and risk of inflammatory bowel disease in patients with an intermediate raised fecal calprotectin: a 'real-world' view.
    McFarlane M; Chambers S; Malik A; Lee B; Sung E; Nwokolo C; Waugh N; Arasaradnam R
    BMJ Open; 2016 Jun; 6(6):e011041. PubMed ID: 27266773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EHealth: self-management in inflammatory bowel disease and in irritable bowel syndrome using novel constant-care web applications. EHealth by constant-care in IBD and IBS.
    Pedersen N
    Dan Med J; 2015 Dec; 62(12):B5168. PubMed ID: 26621403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring Dietitians' Perspectives Toward Current Practices and Services in Relation to Irritable Bowel Syndrome Management in Clinical Settings Across the United Kingdom: A Qualitative Study.
    Belogianni K; Khandige P; Silverio SA; Windgassen S; Moss-Morris R; Lomer M
    J Acad Nutr Diet; 2024 Jul; ():. PubMed ID: 39089620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of a faecal calprotectin care pathway for use in primary care.
    Turvill J; O'Connell S; Brooks A; Bradley-Wood K; Laing J; Thiagarajan S; Hammond D; Turnock D; Jones A; Sood R; Ford A
    Prim Health Care Res Dev; 2016 Sep; 17(5):428-36. PubMed ID: 26899214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Symptoms of irritable bowel syndrome in patients with inflammatory bowel disease: examining the role of sub-clinical inflammation and the impact on clinical assessment of disease activity.
    Berrill JW; Green JT; Hood K; Campbell AK
    Aliment Pharmacol Ther; 2013 Jul; 38(1):44-51. PubMed ID: 23668698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prevalence of irritable bowel syndrome-type symptoms in paediatric inflammatory bowel disease, and the relationship with biochemical markers of disease activity.
    Diederen K; Hoekman DR; Hummel TZ; de Meij TG; Koot BG; Tabbers MM; Vlieger AM; Kindermann A; Benninga MA
    Aliment Pharmacol Ther; 2016 Jul; 44(2):181-8. PubMed ID: 27110920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cognitive behavioural therapy in addition to antispasmodic therapy for irritable bowel syndrome in primary care: randomised controlled trial.
    Kennedy TM; Chalder T; McCrone P; Darnley S; Knapp M; Jones RH; Wessely S
    Health Technol Assess; 2006 Jun; 10(19):iii-iv, ix-x, 1-67. PubMed ID: 16729918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rome III functional constipation and irritable bowel syndrome with constipation are similar disorders within a spectrum of sensitization, regulated by serotonin.
    Shekhar C; Monaghan PJ; Morris J; Issa B; Whorwell PJ; Keevil B; Houghton LA
    Gastroenterology; 2013 Oct; 145(4):749-57; quiz e13-4. PubMed ID: 23872499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is fecal calprotectin always normal in children with irritable bowel syndrome?
    Choi YJ; Jeong SJ
    Intest Res; 2019 Oct; 17(4):546-553. PubMed ID: 31467259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Irritable bowel syndrome in general practice: an overview.
    Oberndorff-Klein Woolthuis AH; Brummer RJ; de Wit NJ; Muris JW; Stockbrügger RW
    Scand J Gastroenterol Suppl; 2004; (241):17-22. PubMed ID: 15696844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A positive diagnostic strategy is noninferior to a strategy of exclusion for patients with irritable bowel syndrome.
    Begtrup LM; Engsbro AL; Kjeldsen J; Larsen PV; Schaffalitzky de Muckadell O; Bytzer P; Jarbøl DE
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):956-62.e1. PubMed ID: 23357491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fecal calprotectin: a marker for clinical differentiation of microscopic colitis and irritable bowel syndrome.
    von Arnim U; Wex T; Ganzert C; Schulz C; Malfertheiner P
    Clin Exp Gastroenterol; 2016; 9():97-103. PubMed ID: 27147826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic constipation diagnosis and treatment evaluation: the "CHRO.CO.DI.T.E." study.
    Bellini M; Usai-Satta P; Bove A; Bocchini R; Galeazzi F; Battaglia E; Alduini P; Buscarini E; Bassotti G;
    BMC Gastroenterol; 2017 Jan; 17(1):11. PubMed ID: 28088179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnosis and management of irritable bowel syndrome: a guide for the generalist.
    Linedale EC; Andrews JM
    Med J Aust; 2017 Sep; 207(7):309-315. PubMed ID: 28954618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.